PRESS RELEASE – IL-17 patent to be granted in the US
PRESS RELEASE – OREGA strengthens its intellectual property in Europe
17 July 2016
IL-17B program to be presented at AACR 2017
27 April 2017
Press Release
Lyon, France, April 18, 2017 – OREGA Biotech, the biotech company committed to the development of novel monoclonal antibody-based immunotherapy for cancer patients, announced today that it has received a notification of allowance from the USPTO stating its intention to grant a patent application filed by OREGA Biotech and related to novel anti-IL-17 antibodies. This patent covers antibodies binding to a functional epitope of IL-17 identified by OREGA Biotech and protects several specific neutralizing antibodies able to bind and inhibit IL-17 homodimer and heterodimer. Based on the date of the priority data, the expected expiration date of this patent is at least until 2032. The related European Patent has already been granted in 2016.
“The delivery of this US Patent is a significant milestone for OREGA Biotech’s IL-17 program. Our business model relies on our ability to discover novel targets and to generate IP rights over targets or broad claims such as functional epitopes”, commented Jeremy Bastid, Chief Operating Officer of OREGA Biotech.
As of today, the patent portfolio of the company is composed of 9 families of patent applications owned or co-owned by OREGA biotech.
